Drug guidance
Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
1 June 2026
-
Published on 01 Aug 2025
Last Updated on 01 Jun 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Tislelizumab 100 mg/10 mL concentrate for solution for infusion, in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have programmed death-ligand 1 (PD-L1) expression on ≥50% of tumour cells, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Funding status
Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2025.
Clinical indication, subsidy class and MediShield Life claims eligibility for tislelizumab are provided in the Annex.